Pluristem Therapeutics Inc. (PSTI - Free Report) recently announced that it will release the results of its phase I/II clinical trial, evaluating the safety and efficacy of PLacental Expanded (PLX-PAD) cells for the treatment of muscle injury, on Jan 21, 2014.
Pluristem develops and manufactures cell therapy products in collaboration with companies like United Therapeutics (UTHR - Free Report) or through research and clinical institutions.
The cells from placenta are derived using the company’s proprietary PluriX therapy and are known as PLacental eXpanded cells. Pluristem's first candidate in development, PLX-PAD, is intended to treat peripheral artery disease (PAD).
We note that Pluristem intends to develop and produce cell therapy products for the treatment of multiple disorders using several methods of administration.
The phase I/II study comprised three treatment groups – two PLX-PAD groups of different doses and one placebo group. The study was initiated in Apr 2013. The primary endpoints of the trial were safety and the maximal contraction force of the gluteal muscle at six months post-surgery while the secondary endpoints included an analysis of the macrostructure and microstructure of the gluteal muscle using magnetic resonance imaging (MRI) and biopsy.
A positive outcome from this study will enable Pluristem to further evaluate the potential of PLX-PAD cells for this indication along with other potential surgical orthopedic injuries and non-surgical sports related injuries. We expect investor focus on results from the trial.
Pluristem currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include Forest Laboratories and Lannett Company, Inc. (LCI - Free Report) with a Zacks Rank #1 (Strong Buy).